The use of probiotics in IBD and IBS

Minerva Pediatrica

Volumn 66, Issue 5, 2014, Pages 491-500

  De Greef, E ^a   Vandenplas, Y ^a   Hauser, B ^a   Devreker, T ^a   Veereman, G ^a  

^a Pediatric Gastroenterology and Nutrition   (Belgium)

Author keywords

Colitis; Crohn disease; Inflammatory bowel diseases; Irritable bowel syndrome; Probiotics; Ulcerative

Indexed keywords

PROBIOTIC AGENT;

CROHN DISEASE; DRUG USE; FECES MICROFLORA; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); REVIEW; STUDY DESIGN; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TRACT; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; CROHN DISEASE; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; META-ANALYSIS AS TOPIC; PROBIOTICS; TREATMENT OUTCOME;

EID: 84923546589     PISSN: 00264946     EISSN: 18271715     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Dave M, Higgins PD, Middha S, Rioux KP The human gut microbiome- current knowledge, challenges, and future directions. Transl Res 2012,160 246-57
2. O'Hara AM, Shanahan F The gut flora as a forgotten organ EMBO Rep 2006,7:688-93.
3. Morelli L. Postnatal Development of intestinal microflora as influenced by infant nutrition J Nutr 2008;138 1791S-1795S
4. Biasucci G, Benenati B, Morelli L, Bessi E, Boehm G. Cesarean Delivery may affect the early biodiversity of intestinal bacteria J Nutr 2008;138:1796S-1800S.
5. Round JL, O'Connell RM, Mazmanian SK Coordination of tolerogenic immune responses by the commensal microbiota J Autoimmun 2010,34 J220-5
6. Wellcome Trust Case Control Consortium et al. Genome-wiDe association study of 14000 cases of seven common diseases and 3,000 shared controls Nature 2007,447 661-78
7. Conte MP, Schippa S, Zamboni I, Penta M, Chianni F, Seganti L et al. Gut-associated bacterial microbiota in paediatnc patients with inflammatory bowel disease Gut 2006;55:1760-7
8. Quigley EM. Bacteria: A new player in gastrointestinal motility disorDers-infections, bacterial overgrowth, and probiotics Gastroenterol Clin North Am 2007,36.735-48, xi.
9. Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the Development of irritable bowel syndrome WMJ 2012;111 17-20.
10. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6.
11. Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Pack-ey CD, Sartor RB et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011;301:G799-807
12. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ. Deane J, Quigley EM et al. An irritable bowel syndrome subtype Defined by species-specific alterations in faecal microbiota. Gut 2012;6l.997-1006.
13. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:513-20, e246-7.
14. Gibson GR, Beatty ER, Wang X, Cummings JH Selective stimulation of bifidobacteria in the human colon by oligofructose and inuhn. Gastroenterology 1995;108 975-82
15. Shanahan F Probiotics and inflammatory bowel disease is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-15
16. Mack DR. Lebel S Role of probiotics in the modulation of intestinal infections and inflammation Curr Opin Gastroenterol 2004;20 22-6
17. Zyrek AA, Cichon C, Helms S. EnDers C, Sonnenborn LI, Schmidt MA Molecular mechanisms unDerlying the probiotic effects of Escherichia coh Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair Cell Microbiol 2007,9 804-16.
18. Gupta P, Andrew H, Kirschner BS, Guandahni S Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-7
19. Schultz M, Timmer A, Herfarth HH, Sartor RB, VanDer-hoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004;4:5
20. Bousvaros A, Guandalim S, Baldassano RN, Botelho C, EVans J, Ferry GD et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease Inflamm Bowel Dis 2005:11.833-9.
21. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharo-myces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000,45 1462-4
22. Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugene L, Dupas JL et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 2013;11:982-7
23. Malchow HA. Crohn's disease and Escherichia coli A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25.653-8.
24. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-A pilot study. Z Gastroenterol 1993;31.129-34.
25. Van Gossum A, Dewit O, Louis E, De Hertogh G, Baert F, Fontaine F et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LAI) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection Inflamm Bowel Dis 2007;13:135-42.
26. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002,51.405-9.
27. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y et al. Ineffectiveness of Lactobacillus johnsonii LAI for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842-7.
28. Akobeng AK, GarDener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005CD003715
29. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A et al. European eviDence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006,55(Suppl l):il6-35
30. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006CD004826.
31. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease Dig Dis Sci 2008;53 2524-31.
32. Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS. Metaanalysis: The effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. Intern Med J 2009;39:103-9
33. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Mo-Deo ME, Gigliobianco A Low-dose balsalaziDe plus a high-potency probiotic preparation is more effective than balsalaziDe alone or mesalazine in the treatment of acute mild-to-moDerate ulcerative colitis. Med Sci Monit 2004;10:PI126-31.
34. Bibilom R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M et al. VSL#3 probiotic-mix-ture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
35. Huynh HQ, DeBruyn J, Guan L, Diaz H, Li M, Girgis S et al. Probiotic preparation VSL.3 induces remission in children with mild to moDerate acute ulcerative colitis a pilot study. Inflamm Bowel Dis 2009;15.760-8
36. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moDerate-ly active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202-9, 1209 el
37. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, trie M, Fukuda K et al. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007:42.1306-11.
38. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitam M, Imaoka A et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133-41.
39. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patnzi G et al. Randomised clinical trial, the effectiveness of Lactobacillus reuten ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012;35:327-34.
40. Guslandi M, Giollo P, Testoni PA A pilot trial of Sac-charomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8
41. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM et al. Treatment of relapsing mild-to-moDerate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105 2218-27.
42. Zocco MA, dal Verme LZ, Cremomni F, Piscaglia AC, Nista EC, CanDelli M et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 2006,231567-74.
43. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coll preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11 853-8
44. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT Non-pathogenic Escherichia coh versus mesalazine for the treatment of ulcerative colitis a randomised trial Lancet 1999,354:635-9-
45. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coh Nissle 1917 is as effective as with standard mesalazine Gut 2004,53:1617-23.
46. Henker J, Muller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: An open-label pilot study Z Gastroenterol 2008,46:874-5.
47. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22.56-63
48. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animahs subsp lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011,5 115-21
49. Gosselink MP, Schouten WR, Van Lieshout LM, Hop WC, Laman JD, Ruseler-Van EmbDen JG Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004;47.876-84.
50. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003;17:509-15.
51. Gionchetti P, Rizzello F, Helwig U, Ventun A, Lam-mers KM, Brigidi P et al. Prophylaxis of pouchitis onset with probiotic therapy a double-blind, placebo-controlled trial Gastroenterology 2003;124:1202-9.
52. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE et al. Maintenance therapy with a probiotic in antibiotic-DepenDent pouchitis- experience in clinical practice. Aliment Pharmacol Ther 2005;22:721-8
53. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000,119:305-9
54. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis Gut 2004;53-108-l4.
55. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tam-basco R, Calabrese C et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007;50.2075-82; discussion 2082-4.
56. Laake KO, Bjorneklett A, Aamodt G, Aabakken L, Jacobsen M, Bakka A et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated lleal-pouch-anal-anastomosis in ulcerative colitis Scand J Gastroenterol 2005 ;40 43-51
57. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011:CD007443
58. Kim HJ, Vazquez Roque MI, Camillen M, Stephens D, Burton DD, Baxter K et al. A randomized controlled trial of a probiotic combination VSL.# 3 and placebo in irritable bowel syndrome with bloating Neurogas-troenterol Motil 2005,17:687-96.
59. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbon-neau D, O'Mahony L et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome Am J Gastroenterol 2006,101:1581-90.
60. Simren M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I et al. Clinical trial the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome -A randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010,31:218-27.
61. Begtrup LM, De MuckaDell OB, Kjeldsen J, Chris-tensen RD, Jarbol De Long-term treatment with probiotics in primary care patients with irritable bowel syndrome-A randomised, double-blind, placebo controlled trial Scand J Gastroenterol 2013;48:1127-35.
62. SonDergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome a randomized, placebo-controlled trial. Scand J Gastroenterol 2011;46 663-72
63. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K et al. Lactobacillus and bifidobacterium in irritable bowel syndrome symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
64. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorDers in children Aliment Pharmacol Ther 2007;25:177-84.
65. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome a randomized, double-blind study. World J Gastroenterol 2012;18:2067-75.
66. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H et al. The effect of a multispecies probiotic mixture on the symptoms and fecal micro-biota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46.220-7
67. Kabir MA, Ishaque SM, All MS, Mahmuduzzaman M, Hasan M. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. My-mensingh Med J 2011;20:397-401.
68. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardn in irritable bowel syndrome effect on quality of life J Clin Gastroenterol 2011;45:679-83
69. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31 655-9-
70. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26 475-86
71. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coll Nissle 1917 in subgroups of patients with irritable bowel syndrome Int J Colorectal Dis 2012,27 467-74.
72. Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT Guidance for substantiating the eviDence for beneficial effects of probiotics: prevention and management of infections by probiotics J Nutr 2010;140-698S-712S
73. Francavilla R, Mimello V, Magista AM, De Camo A, Bucci N, Gagliardi F et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010;126:el445-52
74. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children a double-blind randomized control trial J Pediatr 2005;147 197-201
75. Horvath A, Dziechciarz P, Szajewska H Meta-analysis Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorDers in childhood. Aliment Pharmacol Ther 2011,33 1302-10
76. Guandalim S, Magazzu G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S et al. VSL.#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study J Pediatr Gastroenterol Nutr 2010,51 24-30
77. Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U Therapy options in irritable bowel syndrome Eur J Gastroenterol Hepatol 2010,22.1402-11.
78. Moayyedi P, Ford AC, Talley NJ, Cremonim F, Foxx-Orenstein AE, Brandt LJ et al. The efficacy of probiotics in the treatment of irritable bowel syndrome a systematic review Gut 2010;59 325-32
79. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases PLoS One 2012;7.e34938.
80. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P A systematic review and metaanalysis probiotics in the treatment of irritable bowel syndrome BMC Gastroenterol 2009;9:15.
81. Niedzielin K, KorDecki H, Birkenfeld B A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur I Gastroenterol Hepatol 2001,13.1143-7.
82. Ducrotte P, Sawant P, Jayanthi V Clinical trial- Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome World J Gastroenterol 2012,18 4012-8.
83. Guglielmetti S, Mora D, GschwenDer M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-A double-blind, placebo-controlled study Aliment Pharmacol Ther 2011;33.1123-32.
84. Shanahan F, Quigley EM Manipulation of the microbiota for treatment of IBS and IBD-chal-lenges and controversies. Gastroenterology 2014; 146:1554-63
85. Mercer M, Brinich MA, Geller G, Harrison K, Highland J, James K et al. How patients view probiotics findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome J Clin Gastroenterol 2012;46.138-44
86. Gough E, Shaikh H, Manges AR Systematic review of intestinal microbiota transplantation (fecal bactenot-herapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011,53 994-1002.
87. Borody TJ, Wettstein AR, Leis S, Hills LA, Campbell J, Torres M. Clostridium Difficile complicating inflammatory bowel disease, pre- and post treatment findings. Gastroenterology 2008;134 A361
88. Vermeire SJM, Verbeke K Pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology 2012:S360.
89. AnDerson JL, Edney RJ, Whelan K Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012;36 503-16
90. KunDe S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr et al. Safety, tolerabihty, and clinical response after fecal transplantation in children and young adults with ulcerative colitis J Pediatr Gastroenterol Nutr 2013;56.597-601.
91. Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P et al. Bowel-flora alteration-A potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989;150:604.
92. Andrews PBT Bactenotherapy for chronic consti-pation-A long term follow-up Gastroenterology 1995.A563.